Advent Health

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Source

• Recruiting

  IVUS CHIP UPP Registry

  NCT06625801· Source

• Recruiting

  Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

  NCT06784466· Source

• Recruiting

  Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  NCT07154706· Phase 3· Source

• Recruiting

  Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  NCT06915025· Phase 3· Source

• Active, not recruiting

  Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  NCT06310031· Source

• Active, not recruiting

  Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

  NCT06484114· Source

• Active, not recruiting

  Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

  NCT06267391· Source

• Active, not recruiting

  An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

  NCT06129240· Source

• Recruiting

  A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

  NCT05710848· Phase 1/2· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Source

• Recruiting

  FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  NCT05614739· Phase 1· Source

• Recruiting

  Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  NCT05230173· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Source

• Active, not recruiting

  A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

  NCT04625270· Phase 2· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· Source

• Active, not recruiting

  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

  NCT04561362· Phase 1/2· Source

• Active, not recruiting

  Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

  NCT04416984· Phase 1/2· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Source

• Recruiting

  ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

  NCT03671889· Source

• Active, not recruiting

  Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

  NCT03393884· Phase 1/2· Source

• Active, not recruiting

  Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

  NCT02215265· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Bladder cancer2 recruiting
• Lung cancer2 recruiting
• Ovarian cancer2 recruiting
• Alzheimer disease1 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of CT-868 in Type 1 Diabetes Mellitus

  NCT06062069· Phase 2· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Source